{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:28:43Z","timestamp":1775129323882,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.medcli.2017.10.019","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T19:30:26Z","timestamp":1511724626000},"page":"479-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Tratamiento de la osteoporosis"],"prefix":"10.1016","volume":"150","author":[{"given":"Xavier","family":"Nogu\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Martinez-Laguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2017.10.019_bib0305","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-27-6-861","article-title":"Osteoporosis","volume":"27","author":"Albright","year":"1947","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2017.10.019_bib0310","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1172\/JCI106062","article-title":"Effect of sex hormones on bone in primary osteoporosis","volume":"48","author":"Riggs","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1016\/j.medcli.2017.10.019_bib0315","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1177\/1060028013509233","article-title":"Salmon calcitonin use and associated cancer risk","volume":"47","author":"Overman","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medcli.2017.10.019_bib0320","article-title":"Ten years too long: Strontium ranelate, cardiac events, and the European Medicines Agency","volume":"354","author":"Bolland","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2017.10.019_bib0325","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0025-7753(03)74036-6","article-title":"Osteoporosis 2003","volume":"121","author":"Guanabens","year":"2003","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2017.10.019_bib0330","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rce.2015.08.003","article-title":"Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis posmenop\u00e1usica, glucocorticoidea y del var\u00f3n. Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (3.a versi\u00f3n actualizada 2014)","volume":"215","author":"Gonzalez-Macias","year":"2015","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.medcli.2017.10.019_bib0335","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.medcli.2017.10.019_bib0340","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00198-011-1702-2","article-title":"Fracture liaison services: The UK experience","volume":"22","author":"Mitchell","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0345","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.10.019_bib0350","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0355","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2017.10.019_bib0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0365","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.10.019_bib0370","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.10.019_bib0375","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2017.10.019_bib0380","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0385","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2017.10.019_bib0390","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","article-title":"Epidemiology of osteoporotic fractures","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0395","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","article-title":"A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis","volume":"33","author":"Hiligsmann","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medcli.2017.10.019_bib0400","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000227.pub3","article-title":"Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis","author":"Avenell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2017.10.019_bib0405","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: Evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0410","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0415","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.10.019_bib0420","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-013-2420-8","article-title":"Fracture prevention in patients with cognitive impairment presenting with a hip fracture: Secondary analysis of data from the HORIZON Recurrent Fracture Trial","volume":"25","author":"Prieto-Alhambra","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0425","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.10.019_bib0430","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s001980200114","article-title":"Association between Colles\u2019 fracture and low bone mass: Age-based differences in postmenopausal women","volume":"13","author":"Kanterewicz","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0435","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1210\/jc.2015-2568","article-title":"Bone mineral density as a predictor of subsequent wrist fractures: Findings from the Women's Health Initiative Study","volume":"100","author":"Crandall","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0440","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jbmr.1466","article-title":"The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women","volume":"27","author":"Prieto-Alhambra","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0445","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0450","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/bonekey.2013.138","article-title":"Fracture risk prediction: importance of age, BMD and spine fracture status","volume":"2","author":"Krege","year":"2013","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.medcli.2017.10.019_bib0455","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: A meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0460","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","article-title":"A family history of fracture and fracture risk: a meta-analysis","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2017.10.019_bib0465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: A meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0470","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"Van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2017.10.019_bib0475","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-014-2986-9","article-title":"Incident type 2 diabetes and hip fracture risk: A population-based matched cohort study","volume":"26","author":"Martinez-Laguna","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0480","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2017.10.019_bib0485","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","article-title":"The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: Results from the National Osteoporosis Risk Assessment (NORA)","volume":"17","author":"Siris","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0490","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0495","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.medcli.2017.10.019_bib0505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","article-title":"Osteoporosis management in patients with breast cancer: EMAS position statement","volume":"95","author":"Tremollieres","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.medcli.2017.10.019_bib0510","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: A position statement by the international osteoporosis foundation","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.medcli.2017.10.019_bib0515","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2017.10.019_bib0520","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0378-5122(02)00145-7","article-title":"Bisphosphonates","volume":"43","author":"Diez-Perez","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.medcli.2017.10.019_bib0525","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","article-title":"Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis","volume":"23","author":"Rhee","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0530","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.13-0675","article-title":"Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis","volume":"144","author":"Sharma","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2017.10.019_bib0535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.medcli.2017.10.019_bib0540","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00774-011-0299-z","article-title":"An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence","volume":"3s0","author":"Malden","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0545","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.medcli.2017.10.019_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the american society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0555","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/jbmr.2832","article-title":"Impact of the U.S. Food and Drug Administration's safety-related announcements on the use of bisphosphonates after hip fracture","volume":"31","author":"Kim","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0560","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","article-title":"One and two-year persistence with different anti-osteoporosis medications: A retrospective cohort study","volume":"28","author":"Reyes","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0565","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S2213-8587(17)30178-X","article-title":"Safety of long-term denosumab therapy for osteoporosis","volume":"5","author":"Compston","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.medcli.2017.10.019_bib0570","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.medcli.2017.10.019_bib0575","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.medcli.2017.10.019_bib0580","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.medcli.2017.10.019_bib0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2017.10.019_bib0590","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.medcli.2017.10.019_bib0595","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2017.10.019_bib0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317308187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317308187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T15:35:33Z","timestamp":1535211333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775317308187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0025775317308187"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2017.10.019","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento de la osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2017.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}